Label: TERBUTALINE SULFATE tablet

  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: Abbreviated New Drug Application

Drug Label Information

Updated April 1, 2022

If you are a consumer or patient please visit this version.

  • SPL UNCLASSIFIED SECTION
    Rx Only
  • BOXED WARNING (What is this?)

    WARNING: TOCOLYSIS

    Oral terbutaline sulfate has not been approved and should not be used for acute or maintenance tocolysis. In particular, terbutaline sulfate should not be used for maintenance tocolysis in the outpatient or home setting. Serious adverse reactions, including death, have been reported after administration of terbutaline sulfate to pregnant women. In the mother, these adverse reactions include increased heart rate, transient hyperglycemia, hypokalemia, cardiac arrhythmias, pulmonary edema and myocardial ischemia. Increased fetal heart rate and neonatal hypoglycemia may occur as a result of maternal administration. [see Contraindications, Tocolysis.]

    Close
  • DESCRIPTION
    Terbutaline sulfate USP is a beta-adrenergic agonist bronchodilator available as tablets of 2.5 mg (2.05 mg of the free base) and 5 mg (4.1 mg of the free base) for oral administration ...
  • CLINICAL PHARMACOLOGY
    In vitro and in vivo pharmacologic studies have demonstrated that terbutaline exerts a preferential effect on beta2-adrenergic receptors. While it is recognized that beta2-adrenergic receptors ...
  • INDICATIONS AND USAGE
    Terbutaline sulfate is indicated for the prevention and reversal of bronchospasm in patients 12 years of age and older with asthma and reversible bronchospasm associated with bronchitis and ...
  • CONTRAINDICATIONS
    1. Tocolysis - Oral terbutaline sulfate has not been approved and should not be used for acute or maintenance tocolysis. [see Boxed Warning: Tocolysis.] 2. Hypersensitivity - Terbutaline sulfate ...
  • WARNINGS
    Deterioration of Asthma - Asthma may deteriorate acutely over a period of hours or chronically over several days or longer. If the patient needs more doses of terbutaline sulfate than usual, this ...
  • PRECAUTIONS
    General - Terbutaline, as with all sympathomimetic amines, should be used with caution in patients with cardiovascular disorders, including ischemic heart disease, hypertension, and cardiac ...
  • ADVERSE REACTIONS
    Adverse reactions observed with terbutaline sulfate are similar to those commonly seen with other sympathomimetic amines. All of these reactions are generally transient in nature and usually do ...
  • DOSAGE AND ADMINISTRATION
    Adults - The usual oral dose of terbutaline sulfate for adults is 5 mg administered at approximately six-hour intervals, three times daily, during the hours the patient is usually awake. If side ...
  • OVERDOSAGE
    The median subcutaneous lethal dose of terbutaline sulfate in mature rats is approximately 165 mg/kg (approximately 90 times the maximum recommended daily oral dose for adults on a mg/m2 basis) ...
  • HOW SUPPLIED
    Terbutaline sulfate tablets, USP are packaged in bottles of 100 and 1000 tablets. Descriptions of the 2.5 and 5 mg tablets follow: Tablets 2.5 mg - White to off-white, oval tablets, scored on one ...
  • PRINCIPAL DISPLAY PANEL — 2.5 mg
    NDC 71205-938-30 - TERBUTALINE SULFATE TABLETS, USP - 2.5 mg - Rx Only - 30 TABLETS
  • PRINCIPAL DISPLAY PANEL — 5 mg
    NDC 71205-939-30 - TERBUTALINE SULFATE TABLETS, USP - 5 mg - Rx Only - 30 TABLETS
  • INGREDIENTS AND APPEARANCE
    Product Information